Description
BSE notifies opening of buyback offer by Aurobindo Pharma Limited to repurchase up to 54,23,728 equity shares at Rs.1,475 per share via tender offer route, aggregating up to Rs.800 crore, open from April 23 to April 29, 2026.
Summary
BSE has notified the opening of an Offer to Buy (Buyback) for Aurobindo Pharma Limited under the SEBI-mandated mechanism for acquisition of shares through Stock Exchange pursuant to Tender Offers. The company will buyback up to 54,23,728 fully paid-up equity shares of face value Rs.1 each at a price of Rs.1,475 per share, aggregating up to Rs.800 crore (excluding transaction costs), via the Tender Offer route on a proportionate basis.
Key Points
- Aurobindo Pharma Limited is buying back up to 54,23,728 equity shares (face value Rs.1 each)
- Buyback represents approximately 0.93% of total outstanding equity shares
- Offer price: Rs.1,475 per equity share, payable in cash
- Aggregate buyback size: up to Rs.800,00,00,000 (Rs.800 crore), excluding transaction costs
- Route: Tender Offer through Stock Exchange (BSE)
- Eligible shareholders: Equity Shareholders/Beneficial Owners as on Record Date: Friday, April 17, 2026
- Offer window: Thursday, April 23, 2026 to Wednesday, April 29, 2026
- Letter of Offer is attached to the notice for market participants
Regulatory Changes
No new regulatory changes introduced. The offer is governed by existing SEBI and BSE frameworks:
- SEBI circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015
- SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated December 09, 2016
- BSE notice no. 20170210-16 dated February 10, 2017
- BSE notice no. 20190424-35 dated April 24, 2019
- BSE notice no. 20200528-32 dated May 28, 2020
- BSE notice no. 20201102-43 dated November 02, 2020
- BSE notice no. 20210825-62 dated August 25, 2021
Compliance Requirements
- Trading Members and Custodians must note the offer details and facilitate eligible client participation in the tender offer window
- Participants must comply with the Revised Guidelines of SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated December 09, 2016 and BSE notice no. 20170210-16 dated February 10, 2017 and 20190424-35 dated April 24, 2019
- Eligible shareholders must tender shares through the prescribed BSE acquisition window mechanism
- Further details of the Offer to Buy are available on the BSE website: www.bseindia.com
Important Dates
| Event | Date |
|---|---|
| Notice Date | April 22, 2026 |
| Record Date (Eligible Shareholders) | Friday, April 17, 2026 |
| Offer Opens | Thursday, April 23, 2026 |
| Offer Closes | Wednesday, April 29, 2026 |
Impact Assessment
This buyback is significant for Aurobindo Pharma shareholders and market participants:
- Shareholders on Record Date (April 17, 2026) are eligible to tender shares proportionately at a premium price of Rs.1,475 per share
- The buyback aggregates up to Rs.800 crore, making it a large capital return event for the company
- Trading members and custodians must ensure operational readiness to process client orders through BSE’s tender offer acquisition window during April 23–29, 2026
- The proportionate basis of allotment means not all tendered shares may be accepted if oversubscribed
- At 0.93% of outstanding equity, the buyback has a moderate dilution reversal effect on share capital
Impact Justification
Large-scale buyback of Rs.800 crore by a major pharma company via BSE tender offer route directly affects shareholders and trading members; time-sensitive window of April 23–29, 2026 requires immediate action by eligible participants.